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Abstract 
Our recent studies of microRNA (miRNA) expression signatures indicated that 
microRNA-29a (miR-29a) was significantly downregulated in several types of human cancers, 
suggesting that miR-29a may be a putative tumor-suppressive miRNA in human cancers. The 
aim of this study was to investigate the functional significance of miR-29a in cervical squamous 
cell carcinoma (SCC) and to identify novel miR-29a-regulated cancer pathways and target genes 
involved in cervical SCC oncogenesis and metastasis. Restoration of miR-29a in cervical cancer 
cell lines (CaSKi, HeLa, ME180, and YUMOTO) revealed that this miRNA significantly 
inhibited cancer cell migration and invasion. Gene expression data and in silico analysis 
demonstrated that heat-shock protein 47 (HSP47), a member of the serpin superfamily of serine 
proteinase inhibitors and a molecular chaperone involved in the maturation of collagen 
molecules, was a potential target of miR-29a regulation. Luciferase reporter assays showed that 
miR-29a directly regulated HSP47. Moreover, silencing of the HSP47 gene significantly 
inhibited cell migration and invasion in cancer cells, and the expression of HSP47 was 
upregulated in cancer tissues and cervical intraepithelial neoplasia (CIN), as demonstrated by 
immunostaining. Downregulation of miR-29a was a frequent event in cervical SCC, and 
miR-29a acted as a tumor suppressor by directly targeting HSP47. Recognition of 
tumor-suppressive miRNA-regulated molecular targets provides new insights into the potential 
mechanisms of cervical SCC oncogenesis and metastasis and suggests novel therapeutic 
strategies for treatment of this disease. 
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Introduction 
Cervical cancer is the second most common cause of cancer death in women worldwide, 
and approximately 500,000 new cases of cervical cancer are diagnosed each year, with 280,000 
deaths (1). Cervical squamous cell carcinoma (SCC) is the most frequent type of cervical cancer 
and the most important risk factor for cervical-SCC is persistent human papilloma virus (HPV) 
infection (2-4). High-risk HPVs contain oncoproteins, i.e., E6 and E7, which contribute to the 
oncogenesis of cervical-SCC by silencing tumor-suppressive p53 and Rb proteins and several 
cancer-related genes (5). Therefore, recent research on cervical-SCC has focused on E6 and E7 
oncoproteins. However, the molecular mechanisms of cervical SCC initiation, development, and 
metastasis have not yet been fully elucidated. 
The discovery of noncoding RNAs in the human genome was an important conceptual 
breakthrough in the post-genome sequencing era (6). A growing body of evidence indicates that 
miRNAs are key regulators that contribute to the initiation and development of various types of 
cancer (7). In cancer pathways, normal regulatory mechanisms are disrupted by altered 
expression of tumor-suppressive or oncogenic miRNAs. Therefore, identification of 
differentially expressed miRNAs is an important step to understanding human oncogenesis. 
Based on this, our research group has elucidated the miRNA expression signatures of 
various types of human cancers (8-12). Recent studies of miRNA expression signatures of 
hypopharyngeal SCC and maxillary SCC have indicated that expression of miRNA-29 family 
miRNAs (miR-29a/b/c) is significantly reduced in cancer tissues, suggesting that these miRNAs 
may contribute to the oncogenesis and metastasis of cervical SCC (13, 14).  
Expression analysis of miR-29 family miRNAs in cervical SCC clinical specimens 
showed that miR-29a was the most highly downregulated miRNA in the clinical specimens, thus, 
we focused on miR-29a in this study. The aim of the present study was to investigate the 
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functional significance of miR-29a and to identify the molecular target genes regulated by 
miR-29a in cervical SCC cells. Genome-wide gene expression data and in silico database 
analysis showed that the heat-shock protein 47 (HSP47) gene, also known as serpin peptidase 
inhibitor clade H (SERPINH1), was a promising candidate target of miR-29a. 
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Materials and Methods 
Clinical specimens    
A total of 18 primary cervical SCC specimens and 11 noncancerous specimens were 
collected from patients who had undergone surgical treatment at Chiba University Hospital. The 
samples were processed and stored in liquid nitrogen until RNA extraction. Patient information 
is summarized in Table 1. Our study was approved by the Bioethics Committee of Chiba 
University; prior written informed consent and approval was given by each patient. HPV status 
was examined by L1 consensus primers and type-specific real-time PCR primers, as described 
previously (15). 
 
RNA isolation  
Total RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s protocol. RNA concentrations were determined 
spectrophotometrically. RNA quality was confirmed using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, USA). 
 
Quantitative real-time RT-PCR  
Stem-loop RT-PCR (TaqMan MicroRNA Assays; P/N: 002112 for miR-29a, P/N: 000413 
for miR-29b, P/N: 000587 for miR-29c; Applied Biosystems, Foster City, CA, USA) was used to 
quantify miRNAs according to earlier published conditions(14). To normalize the data for 
quantification of miR-29-family sequences, we used RNU48 (AssayID: 001006; Applied 
Biosystems) as a control. The delta–delta Ct method was used to calculate the fold-change. 
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Mature miRNA and siRNA transfections  
Cervical cancer cell lines were transfected with Lipofectamine RNAiMAX transfection 
reagent (Invitrogen) and Opti-MEM (Invitrogen) with 10 nM mature miRNA or siRNA 
molecules. The following RNA species were used in this study: mature miRNA, mirVana 
miRNA mimic for hsa-miR-29a-3p (Product ID: MC12499; Applied Biosystems), negative 
control miRNA (P/N: AM17111; Applied Biosystems), small-interfering RNA (Stealth siRNAs, 
si-SERPINH1, P/N: HSS101423 and HSS189522; Invitrogen), and negative control siRNA 
(Stealth RNAi Negative Control Medium GC Duplex, P/N: 12935-300, Invitrogen).  
 
Cell proliferation, migration, and invasion assays   
Cell proliferation was determined using XTT assays (Roche Applied Science, Tokyo, 
Japan) according to the manufacturer’s instructions.  
Cell migration assays were performed using modified Boyden Chambers (Transwells, 
Corning/Costar #3422, USA). Cells were transfected with 10 nM miRNA by reverse 
transfection and plated in 10-cm dishes at 8 × 105 cells/dish. After 48 h, 1 × 105 cells were 
added to the upper chamber of each migration well and were allowed to migrate for 48 h. After 
gentle removal of the nonmigratory cells from the filter surface of the upper chamber, the cells 
that migrated to the lower side were fixed and stained with Diff-Quick (Sysmex Corporation, 
Japan). The number of cells migrating to the lower surface was determined microscopically by 
counting four areas of constant size per well. 
Cell invasion assays were carried out using modified Boyden chambers in 24-well tissue 
culture plates at 1 × 105 cells per well (BD Biosciences, USA). All experiments were performed 
in duplicate. 
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Target gene search for miR-29a  
A genome-wide screen was performed to identify miR-29a-target genes using 
miR-29a-transfected CaSKi cells. A SurePrint G3 Human GE 8x60K Microarray (Agilent 
Technologies, Santa Clara, CA, USA)) was used for expression profiling of miR-29a 
transfectants in comparison with miRNA-negative control transfectants. TargetScan release 6.2 
(http://www.targetscan.org/) was used to identify predicted target genes and their miRNA 
binding site seed regions. Gene expression data for clinical cervical SCC specimens were 
obtained from the GEO database (accession number GSE6791).  
 
Western blot analysis 
Cells were harvested and lysed 72 h after transfection. Each cell lysate (50 μg of protein) 
was separated using Mini-PROTEAN TGX gels (Bio-Rad, Hercules, CA, USA), followed by 
subsequent transfer to PVDF membranes. Immunoblotting was performed with polyclonal 
anti-HSP47 antibodies (sc-5293; Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Anti-GAPDH antibodies (ab8245; Abcam, UK) were used as an internal control.  
 
Plasmid construction and dual-luciferase reporter assays 
Partial sequences (191 bp) of the HSP47 3’ untranslated region (3’UTR) that contain the 
miR-29a target site (GGTGCTA) were inserted between the XhoI and PmeI restriction sites in 
the 3’UTR of the hRluc gene in the psiCHECK-2 vector (Promega, Madison, WI, USA). The 
deletion of the miR-29a target site was cloned and constructed as deletion-vector in this study. 
HeLa cells were then transfected with five ng vector and 10 nM mature miRNA.  
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Immunohistochemistry 
We performed immunostaining using a tissue microarray containing 60 specimens: 10 
normal cervical tissues, 10 inflammation tissues, 10 cervical intra-epithelial neoplasia (CIN) 
tissues, and 30 SCC tissues (CR 602; US Biomax, Rockville, MD, USA). Detailed information 
on all tumor specimens can be found at http://www.biomax.us/tissue-arrays/Uterus/CR602. The 
tissue microarray was incubated overnight with primary mouse monoclonal antibodies against 
HSP47 (1:50, sc-5293, Santa Cruz Biotechnology). Next, the sample was treated with 
anti-mouse-biotin antibodies (1:2000, 115-065-003, Jackson ImmunoResearch Laboratories, 
Inc., West Grove, PA, USA) for 1 h and then treated with an ABC kit (K0377, DAKO, 
Carpinteria, CA, USA) for 30 min. Counterstaining was performed using a DAB kit (425011, 
Nichirei Bioscience Inc., Tokyo, Japan). 
Immunostaining was evaluated according to previously described scoring methods (12).  
 
Statistical analysis   
The relationships between two variables and numerical values were analyzed using the 
Mann-Whitney U test, and the relationships between three variables and numerical values were 
analyzed using the Bonferroni-adjusted Mann-Whitney U test. Expert Stat View analysis 
software (ver. 4; SAS Institute Inc., Cary, NC, USA) was used in both analyses. In the 
comparison of three variables, an unadjusted statistical level of significance of P < 0.05 
corresponded to the Bonferroni-adjusted level of P < 0.0167. 
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Results 
Expression of miR-29-family miRNAs in clinical cervical SCC specimens 
The sequences and chromosomal locations of miR-29-family miRNAs (miR-29a/b/c) in 
the human genome are shown in Figure 1A. These miRNAs were clustered at two different 
human genomic loci, miR-29b-1 and miR-29a at 7q32.3 and miR-29b-2 and miR-29c at 1q32.2. 
We evaluated the expression of miR-29-family miRNAs in 18 clinical specimens and 11 
noncancerous tissues. The expression levels of miR-29a and miR-29c were significantly lower 
in tumor tissues than in noncancerous tissues. However, there was no significant difference in 
the expression of miR-29b (Figure 1B). When we compared two miRNAs (miR-29a and 
miR-29c) after normalization to the expression of RNU48, miR-29a was more abundantly 
expressed in both normal and cancerous tissues.  
 
Effects of restoring miR-29a on cell proliferation, migration, and invasion in cervical SCC 
cell lines 
To investigate the functional effects of miR-29a, we performed gain-of-function studies 
using miRNA transfection in four cervical cancer cell lines. XTT assays demonstrated that cell 
proliferation was significantly inhibited in miR-29a transfectants in comparison with mock- or 
miR-control-transfected CaSKi, HeLa, and ME180 cells; no inhibition was observed in 
YUMOTO cells this assay (Figure 2A). We observed the following changes in proliferation, 
expressed as a percentage of mock-transfected cells:(1) CaSKi: mock, 100.0% ± 8.2%; 
miR-control, 97.9% ± 6.6%; miR-29a, 87.6% ± 5.9%;  p = 0.0032, (2) HeLa: mock, 100.0% ± 
7.5%; miR-control, 97.6% ± 4.1%; miR-29a, 73.8% ± 4.8%; p < 0.0001,(3) ME180: mock, 
100.0% ± 4.5%; miR-control, 93.4% ± 5.9%; miR-29a, 75.1% ± 4.7%; p < 0.0001, and (4) 
YUMOTO: mock, 100.0% ± 8.0%; miR-control, 99.9% ± 10.6%; miR-29a, 85.0% ± 9.9%; p = 
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0.0287 (Figure 2A).  
Migration assays demonstrated that miR-29a transfection significantly inhibited cell 
migration compared with mock- or miR-control-transfected cells. We observed the following 
changes in migration activity, expressed as a percentage of mock-transfected cells:(1) CaSKi: 
mock, 100.0% ± 14.0%; miR-control, 116.1% ± 19.3%; miR-29a, 31.7% ± 5.7%;  p < 0.0001, 
(2) HeLa: mock, 100.0% ± 11.3%; miR-control, 124.0% ± 14.8%; miR-29a, 55.3% ± 10.6%; p 
< 0.0001,(3) ME180: mock, 100.0% ± 12.4%; miR-control, 89.8% ± 16.8%; miR-29a, 20.3% ± 
6.4%; p < 0.0001,(4) YUMOTO: mock, 100.0% ± 8.1%; miR-control, 95.4% ± 15.8%; miR-29a, 
13.0% ± 6.3%; p < 0.0001 (Figure 2B).  
Finally, Matrigel invasion assays demonstrated that cell invasion was significantly 
inhibited in miR-29a transfectants in comparison with mock- or miR-control-transfected cells 
for all cell lines tested. We observed the following changes in invasion activity, expressed as a 
percentage of mock-transfected cells:(1) CaSKi: mock, 100.0% ± 12.9%; miR-control, 103.4% 
± 6.3%; miR-29a, 16.6% ± 7.5%; p < 0.0001, (2) HeLa: mock, 100.0% ± 16.5%; miR-control, 
102.7% ± 14.6%; miR-29a, 31.8% ± 13.2%; p < 0.0001,(3) ME180: mock, 100.0% ± 22.7%; 
miR-control, 109.5% ± 37.6%; miR-29a, 23.8% ± 6.6%; p < 0.0001,(4) YUMOTO: mock, 
100.0% ± 11.9%; miR-control, 90.9% ± 10.1%; miR-29a, 5.9% ± 3.3%; p < 0.0001 (Figure 2C).  
 
Identification of miR-29a-regulated putative target genes 
To identify genes regulated by miR-29a, we used in silico and genome-wide gene 
expression analyses. The strategy for the selection of miR-29a-target genes is shown in Figure 3. 
First, to gain further insight into which genes were affected by miR-29a, we performed 
genome-wide gene expression analysis using miR-29a-transfected CaSKi cells; 986 genes were 
identified as downregulated (log2 ratio < -1.0) by miR-29a transfection. Next, we used the 
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TargetScan database to examine whether these genes contained miR-29a binding sequences in 
their 3’UTRs. Finally, the gene set was analyzed with a publicly available gene expression data 
set in the GEO (accession number: GSE6791), and genes upregulated (log2 ratio > 1.5) in 
cervical SCC were chosen. A total of 29 genes were candidate miR-29a-regulated oncogenic 
genes in cervical SCC (Table 2). 
As a result of our selection strategy, we identified HSP47 as one of the most highly 
upregulated genes in cervical SCC tissues and one of the most significantly downregulated 
genes in miR-29a-transfected cells.  
 
HSP47 was directly regulated by miR-29a 
We performed qRT-PCR and western blotting in HeLa cells to investigate whether HSP47 
expression was reduced by restoration of miR-29a. The mRNA and protein expression levels of 
HSP47 were significantly repressed in miR-29a transfectants in comparison with mock- or 
miR-control-transfected cells (Figure 4A and 4B).  
To determine whether the 3’UTR of HSP47 mRNA had an actual target site for miR-29a, 
we performed luciferase reporter assays using a vector encoding the 3’UTR of HSP47 mRNA. 
We found that the luminescence intensity was significantly reduced by transfection with 
miR-29a and the vector carrying the wild-type 3’UTR of HSP47, whereas transfection with a 
deletion vector blocked the decrease in luminescence (Figure 4C). 
 
Effects of silencing HSP47 on cell proliferation, migration, and invasion in cervical SCC 
cell lines 
To investigate the functional role of HSP47, we performed loss-of-function studies using 
si-HSP47-transfected CaSKi and HeLa cells. First, we evaluated the knockdown efficiency of 
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si-HSP47 transfection. The expression of HSP47 mRNA was repressed in two si-HSP47 
transfectants as compared with mock and si-control transfectants (P < 0.0083; Figure 5A). 
Moreover, the expression of HSP47 protein was repressed in si-HSP471-1 and si-HSP47-2 
transfectants as compared with mock and si-control transfectants (Figure 5B). These results 
showed that the two siRNAs were effective for loss-of-function assays in this study. 
In CaSKi and HeLa cells, XTT assays revealed significant inhibition of cell proliferation 
following transfection with the two different siRNAs targeting HSP47 as compared with the 
growth of mock- and si-control-transfected cells. The following changes in growth were 
observed, expressed as a percentage of control proliferation: (1) CaSKi: mock, 100.0% ± 4.7%; 
miR-control, 87.0% ± 5.7%; si-HSP47-1, 66.4% ± 5.5%; si-HSP47-2, 63.1% ± 7.8%; (2) HeLa: 
mock, 100.0% ± 8.5%; miR-control, 100.7% ± 8.7%; si-HSP47-1, 65.9% ± 7.4%; si-HSP47-2, 
33.0% ± 8.7% (Figure 6A). 
Moreover, migration assays demonstrated that cell migration was significantly inhibited 
in CaSKi and HeLa cells transfected with the two different si-HSP47 constructs. The following 
changes in migration were observed, expressed as a percentage of control migration: (1) CaSKi: 
mock, 100.0% ± 13.7%; miR-control, 129.8% ± 9.9%; si-HSP47-1, 17.1% ± 7.4%; si-HSP47-2, 
57.7% ± 5.3%; (2) HeLa: mock, 100.0% ± 8.1%; miR-control, 74.3% ±  9.8%; si-HSP47-1, 
24.5% ± 3.5%; si-HSP47-2, 22.9% ± 4.7% (Figure 6B). 
Matrigel invasion assays demonstrated that cell invasion was significantly inhibited in 
CaSKi and HeLa cells transfected with the two different si-HSP47 constructs. The following 
changes in invasion were observed, expressed as a percentage of control invasion: (1) CaSKi: 
mock, 100.0% ± 24.5%; miR-control, 128.0% ± 18.9%; si-HSP47-1, 13.3% ± 13.8%; 
si-HSP47-2, 63.3% ± 24.9%; (2) HeLa: mock, 100.0% ±  13.1%; miR-control, 97.8% ± 
17.4%; si-HSP47-1, 32.3% ± 9.7%; si-HSP47-2, 43.2% ± 5.2% (Figure 6C). 
12 
 
Immunohistochemistry of HSP47 in a tissue microarray 
Finally, we confirmed the expression levels of HSP47 in normal cervical tissues, CIN 
tissues, and cancer tissues by immunohistochemical staining. Very low expression of HSP47 
was observed in normal tissues (Figure 7A). In CIN, weak expression of HSP47 was observed 
(Figure 7B). In contrast, HSP47 was more strongly expressed in several tumor lesions compared 
to normal tissues and CIN tissues (Figure 7C and 7D). The expression score of HSP47 in 
cervical SCC was significantly higher than that in CIN (P = 0.0001) and normal tissues (P < 
0.0001; Figure 7E). 
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Discussion 
Aberrant expression of the miR-29 family miRNAs has been reported in several types of 
human cancers; however, the expression status varies according to the cancer type. Decreased 
expression of the miR-29 family has been observed in cholangiocarcinoma, nasopharyngeal 
cancer, non-small cell lung cancer, hepatocellular carcinoma, malignant peripheral nerve sheath 
tumors, and mantle cell lymphoma. In contrast, upregulation of the miR-29 family was reported 
in breast cancer, colon cancer, and acute myeloid leukemia(16). In cervical cancer, it was 
reported that mir-29 targets the HPV-related gene (17). In this study, our data demonstrated that 
miR-29a was significantly downregulated in cervical SCC clinical specimens and cell lines, 
regardless of the type of HPV infection. Furthermore, restoration of miR-29a in cervical cancer 
cells inhibited cancer cell migration and invasion, suggesting that miR-29a functions as a tumor 
suppressor and may contribute to metastasis in cervical SCC. 
The molecular mechanism through which miR-29a is silenced in cervical SCC is still 
unknown. Analysis of the promoter region of miR-29-family miRNAs in the human genome has 
revealed that the miR-29b-1/miR-29a promoter region contains two putative E-box sites 
(MYC-binding sites), a Gli-binding site, and four NF-κB-binding sites (18). Moreover, increased 
expression of the MYC oncogene silences miR-29b-1/miR-29a expression, and NF-κB signaling, 
which is known to be activated in inflammation-related cancers, directly represses 
miR-29b-1/miR-29a promoter activity (19). Thus, it will be necessary to identify the 
transcription factors that contribute to the silencing of the miR-29 family in cervical SCC. 
Although miR-29b-1/miR-29a and miR-29b-2/miR-29c form cluster miRNAs, are located within 
the same chromosomal regions, and share transcriptional units, the expression of miR-29b was 
not reduced in cancer tissues compared to normal tissues in this study. The reason for this is not 
yet clear, and further elucidation of the molecular mechanisms controlling the expression of 
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miR-29 family miRNAs in cancer cells is necessary. 
MiRNAs are unique in their ability to regulate many protein coding genes. Bioinformatic 
predictions have indicated that miRNAs regulate more than 30% of protein coding genes (20). 
Aberrant expression of miRNAs causes destruction of tightly regulated miRNA/protein-coding 
RNA networks in human cancer cells. Therefore, identification of aberrantly expressed 
miRNA-mediated cancer pathways and target genes is the first step in elucidating the role of 
miRNAs in human cancers.  
According to gene expression data and in silico database analysis, a total of 29 genes 
were selected as candidate miR-29a targets. Previous reports have indicated that the miR-29 
family plays a dominant role in the regulation of extracellular matrix (ECM) genes. Indeed, 
luciferase reporter assays demonstrated that miR-29a directly targeted HSP47, a 
collagen-binding, heat-inducible glycoprotein. This is the first report demonstrating that HSP47 
was regulated by tumor-suppressive miR-29a in cervical SCC.  
HSP47, a 47-kDa heat-shock protein, was first identified in fibroblasts (21) and is located 
within the human chromosome 11q13.5 region, which is frequently amplified in several types of 
human cancers, including cervical SCC (22). Moreover, HSP47 is localized in the endoplasmic 
reticulum, a cellular organelle involved in the intercellular processing and secreting of 
procollagens (23). Many studies have demonstrated that HSP47 is overexpressed in many 
fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, cardiac fibrosis, and liver 
cirrhosis (24). Fibrosis is a common disease of organ dysfunction and is closely associated with 
ECM proteins, such as collagens, actins, and fibronectins (25). Interestingly, members of the 
miR-29 family have been shown to be involved in regulating ECM proteins, and multiple 
studies have indicated that aberrant expression of miR-29 family members contributes 
substantially to the development of disease (26). Thus, downregulation of the miR-29 family 
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and dysregulation of HSP47 and ECM components are key events contributing to the 
pathogenesis of diseases, suggesting that these molecules are potential therapeutic targets. 
Overexpression of HSP47 has been reported in pancreatic cancer, gastric cancer, and head 
and neck squamous cell carcinoma (27-29). Our present data also support previous reports, 
suggesting that silencing of miR-29a caused overexpression of HSP47 and was an important 
event in the pathogenesis of cervical SCC, contributing to cancer cell migration and invasion in 
particular. The epithelial-to-mesenchymal transition (EMT) is a fundamental biological process 
whereby epithelial cells lose their polarity and undergo a transition to a mesenchymal phenotype 
(30). Initiation of the EMT requires external signals, such as epidermal growth factor (EGF), 
fibroblast growth factor (FGF), hepatocyte growth factor (HGF), and transforming growth 
factor-beta (TGF-β) (31). The TGF-β pathway is a prominent inducer of the EMT, and 
expression of the miR-29 family has been shown to have an inverse relationship with the TGF-β 
pathway. Restoration of miR-29 family members directly suppresses TGF-β1 and TGF-β2 and 
disrupts the expression of ECM proteins (32). Furthermore, ECM molecules, including collagen 
type I, promote the EMT through integrin and discoidin domain receptor-1 signaling (33, 34). 
Thus, the understanding of molecular pathways and targets regulated by the tumor-suppressive 
miR-29 family may provide new insights into the EMT process in cervical SCC and facilitate 
the development of more effective strategies for future therapeutic interventions for this disease.  
In conclusion, downregulation of miR-29a was a frequent event in cervical SCC. 
Moreover, tumor-suppressive miR-29a directly regulated HSP47, a molecular chaperone 
involved in the maturation of collagen molecules. Restoration of miR-29a or silencing of HSP47 
inhibited cancer cell migration and invasion, suggesting that the miR-29a-HSP47 pathway 
contributes to the metastasis of cervical SCC. Identification of molecular targets regulated by 
tumor-suppressive miRNAs will provide insights into the potential mechanisms of cervical SCC 
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oncogenesis and metastasis, facilitating the development of novel therapeutic strategies for the 
treatment of this disease. 
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Table 1 
Characteristics of cervical-SCC specimens and noncancerous specimens  
Cervical-SCC specimens 
Patient 
No. 
Age 
FIGO 
Stage 
Tumor size (cm2) 
Lymph node 
metastasis 
HPV 
status 
1 58 IIB 1.7 × 1.9 - 16 
2 64 IIB No data  - 16 
3 37 IIB 3.5 × 3.0 + 16 
4 41 IB2 8.3 × 3.3 - 16 
5 39 IB1 3.5 × 3.4 - 16 
6 34 IB1 3.2 × 2.2 - 16 
7 43 IB2 4.0 × 8.0 - 18 
8 56 IIIB 3.0 × 3.1 + 16,18 
9 77 IIB 3.0 × 2.7 - 16 
10 62 IB1 3.0 × 2.0 - 16 
11 56 IIIA 4.5 × 2.2 + 16 
12 56 IIA 4.0 × 4.0 - 16 
13 60 IB1 4.0 × 4.0 - 16 
14 32 IIB 6.0 × 3.0 + 16 
15 38 IB2 6.8 × 4.6 + 16 
16 44 IB1 3.5 × 2.2 - 16 
17 40 IB1 3.0 × 2.0 - 16 
18 63 IB1 2.7 × 2.4 - 16 
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noncancerous specimens  
Patient 
No. 
Age HPV status 
1 44 - 
2 77 - 
3 75 - 
4 45 - 
5 47 - 
6 69 - 
7 40 - 
8 48 - 
9 41 - 
10 41 - 
11 34 - 
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Table 2 
Candidate target genes regulated by miR-29a 
Expression 
(log2 ratio) 
  
 
CSCC 
clinical 
specimen  
miR-29a 
trans- 
fectant 
Entrez 
Gene ID 
Symbol Gene name 
7.32 -3.37 871 HSP47 heat shock protein 47 
4.75 -3.04 4678 NASP nuclear autoantigenic sperm protein 
4.69 -1.67 10951 CBX1 chromobox homolog 1 
3.29 -1.68 144455 E2F7 E2F transcription factor 7 
3.08 -2.25 4291 MLF1 myeloid leukemia factor 1 
3.07 -4.27 55920 RCC2 regulator of chromosome condensation 2 
2.91 -1.50 23186 RCOR1 REST corepressor 1 
2.77 -4.11 3300 DNAJB2 DnaJ (Hsp40) homolog, subfamily B, member 2 
2.64 -2.66 3655 ITGA6 integrin, alpha 6 
2.63 -2.97 79017 GGCT gamma-glutamylcyclotransferase 
2.47 -1.31 8936 WASF1 WAS protein family, member 1 
2.26 -1.26 4140 MARK3 MAP/microtubule affinity-regulating kinase 3 
2.10 -1.15 54851 ANKRD49 ankyrin repeat domain 49 
1.91 -1.56 9949 
AMMECR
1 
Alport syndrome, mental retardation, midface 
hypoplasia and elliptocytosis chromosomal 
region gene 1 
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1.87 -1.85 22877 MLXIP MLX interacting protein 
1.85 -1.49 8894 EIF2S2 
eukaryotic translation initiation factor 2, subunit 
2 beta, 38kDa 
1.85 -1.40 3927 LASP1 LIM and SH3 protein 1 
1.84 -1.42 54107 POLE3 
polymerase (DNA directed), epsilon 3 (p17 
subunit) 
1.80 -1.24 4361 MRE11A 
MRE11 meiotic recombination 11 homolog A 
(S. cerevisiae) 
1.79 -1.56 7328 UBE2H ubiquitin-conjugating enzyme E2H 
1.75 -4.69 3915 LAMC1 laminin, gamma 1 (formerly LAMB2) 
1.67 -1.57 80829 ZFP91 zinc finger protein 91 homolog (mouse) 
1.65 -2.31 8527 DGKD diacylglycerol kinase, delta 130kDa 
1.61 -3.07 4232 MEST mesoderm specific transcript homolog (mouse) 
1.60 -2.75 7168 TPM1 tropomyosin 1 (alpha) 
1.59 -1.62 9618 TRAF4 TNF receptor-associated factor 4 
1.56 -1.28 23380 SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 
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Figure legends 
Figure 1 
(A) The sequences and chromosomal locations of miR-29-family miRNAs. 
Seed sequences were shown in underlines.  
(B)Expression levels of miR-29a/b/c in cervical-SCC tumor tissues and normal tissues, as 
determined by Stem-loop RT-PCR. RNU48 was used as an internal control. 
 
Figure 2 
Effects of miR-29a restoration on the proliferation, migration, and invasion of cervical-cancer 
cell lines (CaSKi, ME180, HeLa, and YUMOTO). 
(A) Proliferation activities of cervical-cancer cell lines as determined by XTT assays. *P < 
0.0167. 
(B) Migration activities of cervical-cancer cell lines as determined by migration assays. *P < 
0.0167. 
(C) Invasion activities of cervical-cancer cell lines as determined by Matrigel invasion assays. 
*P < 0.0167. 
 
Figure 3 
Identification of miR-29a regulated molecular targets.  
A total of 986 genes were identified by the miR-29a transfection into CaSKi cell. Among them, 
119 genes have miR-29a target sites in their 3’ UTR. Finally, 29 genes were upregulated in 
cervical SCC clinical specimens by using expression data of GEO database (accession numbers; 
GSE6791). 
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Figure 4 
miR-29a directly regulated HSP47 in HeLa cells.  
(A) mRNA expression of HSP47 as measured by qRT-PCR. GUSB was used as an internal 
control. *P < 0.0167.  
(B) Expression of HSP47 protein as measured by western blot analysis. GAPDH was used as a 
loading control.  
(C) A putative miR-29a binding site in the 3’UTR of HSP47 mRNA was identified using the 
TargetScan database. Luciferase reporter assays were performed using a vector encoding the 
partial sequences of the 3’UTR containing the putative miR-29a target site. The vector (10 ng) 
and 10 nM miR-29a or miR-control were cotransfected into HeLa cells. Renilla luciferase 
activity was measured 24 h after transfection. The results were normalized to firefly luciferase 
values. *P < 0.05.  
 
Figure 5 
HSP47 mRNA and protein expression levels were suppressed by si-HSP47 transfection in 
CaSKi and HeLa cells. 
(A) Expression of HSP47 mRNA as revealed by real-time qRT-PCR. *P < 0.0083.  
(B) Expression of HSP47 protein as revealed by western blot analysis. GAPDH was used as a 
loading control.  
 
Figure 6 
Effects of HSP47 knockdown by si-HSP47 transfection in CaSKi and HeLa cells. 
(A) Cell proliferation activities in CaSKiand HeLa cells as measured by XTT assays. *P < 
0.0083.  
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(B) Cell migration activities in CaSKi and HeLa cells. *P < 0.0083. (C) Cell invasion activities 
in CaSKi and HeLa cells. *P < 0.0083. 
 
Figure 7 
Immunohistochemical staining of HSP47 in SCC (n = 30), CIN (n = 10), and normal cervical 
tissue (n = 20) by tissue microarray.  
(A) Negative staining in normal cervical tissue; (B) a weakly stained tumor lesion; (C) a 
strongly stained tumor lesion; and (D) a moderately stained tumor lesion. 
(E) Quantification of HSP47 expression. The expression of HSP47 was upregulated in cervical 
SCC specimens compared with CIN and normal cervical tissue (P < 0.0001). 
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